Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
June 24, 2021 08:19 ET
|
Biomerica, Inc.
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced...
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 29, 2021 16:01 ET
|
Phathom Pharmaceuticals
Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapyNew Drug Application (NDA) submissions targeted...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
March 30, 2021 16:05 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 19, 2021 08:30 ET
|
Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
August 06, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
July 27, 2020 07:00 ET
|
RedHill Biopharma Ltd.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to...
Phathom Pharmaceuticals Provides Clinical Trial Status Update
June 15, 2020 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
July 03, 2019 07:00 ET
|
RedHill Biopharma Ltd.
U.S. FDA accepts NDA for priority review PDUFA date set for November 2, 2019 H. pylori infection affects approximately 35% of the U.S. population and is the strongest risk factor for the development...
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
January 17, 2019 08:00 ET
|
RedHill Biopharma Ltd.
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to...
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
December 03, 2018 07:01 ET
|
RedHill Biopharma Ltd.
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p<0.0001) High resistance to...